3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Active not recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
2
Tumor-Agnostic
1
Conditions
Breast Neoplasms
9
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
105
Specimen Handling
55
Magnetic Resonance Spectroscopy
48
Biopsy
47
Nivolumab
40
Paclitaxel
35
Gemcitabine
30
Radiosurgery
29
Carboplatin
28
Irinotecan
22
Ipilimumab
22
Cyclophosphamide
22
Cisplatin
22
trastuzumab deruxtecan
21
Leucovorin
19
Capecitabine
19
Fluorouracil
18
Cetuximab
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
18
Pemetrexed
17
Fulvestrant
17
Drug Therapy
16
Docetaxel
16
Taxes
15
Oxaliplatin
15
olaparib
14
abemaciclib
14
Radiotherapy
14
palbociclib
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
AZD9833
×
1 year
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04214288
2025-11-20
SERENA-2
AstraZeneca
Phase 2
Active not recruiting
240 enrolled
16 charts
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled